Nov 19, 2015
Amgen's Repatha Is Too Bloody Pricey for the U.K.
Amgen’s Repatha Is Too Bloody Pricey for the U.K.
Commercializing Amgen‘s recently approved cholestserol fighter Repatha across the EU hit a road block this week when cost crunchers in the U.K. determined that the drug didn’t deliver the right balance of efficacy and price.
Not good enough Unlike the U.S., where Medicare is unable to negotiate prices directly with drugmakers, drugs have to pass cost hurdles in the U.K. that demonstrate an…
View On WordPress